(Q34114035)

31 July 2017

1 reference

title

Lisdexamfetamine dimesylate: a prodrug stimulant for the treatment of ADHD in children and adults (English)

1 reference

31 July 2017

Lisdexamfetamine Dimesylate: A Prodrug Stimulant for the Treatment of ADHD in Children and Adults (English)

0 references

author name string

Gregory Mattingly

series ordinal

1

1 reference

31 July 2017

publication date

1 May 2010

1 reference

31 July 2017

May 2010

0 references

published in

C N S Spectrums

1 reference

31 July 2017

volume

15

1 reference

31 July 2017

issue

5

1 reference

31 July 2017

05

0 references

page(s)

315-325

1 reference

Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

Confirmatory factor analysis of the Behavior Rating Inventory of Executive Function (BRIEF) in a clinical sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

Executive function impairments in children with attention-deficit hyperactivity disorder: do they differ between school and home environments?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

Molecular genetics of attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

Advances in the Pharmacotherapy of Attention‐Deficit‐Hyperactivity Disorder: Focus on Methylphenidate Formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

7 January 2021

Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

7 January 2021

The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

7 January 2021

Emotional expression in children treated with ADHD medication: development of a new measure

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

7 January 2021

Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027541

7 January 2021

10.1017/S1092852900027541

Identifiers

DOI

0 references

1 reference